Submissions for variant NM_000059.3(BRCA2):c.2240A>G (p.Glu747Gly) (rs397507283)

Total submissions: 8

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Invitae	RCV000204756	SCV000262417	uncertain significance	Hereditary breast and ovarian cancer syndrome	2018-08-06	criteria provided, single submitter	clinical testing	This sequence change replaces glutamic acid with glycine at codon 747 of the BRCA2 protein (p.Glu747Gly). The glutamic acid residue is weakly conserved and there is a moderate physicochemical difference between glutamic acid and glycine. This variant is present in population databases (rs397507283, ExAC 0.03%). This variant has been reported in an individual with breast cancer in the Leiden Open-source Variation Database (PMID: 21520333). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The glycine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics	RCV000215823	SCV000277257	uncertain significance	Hereditary cancer-predisposing syndrome	2019-03-30	criteria provided, single submitter	clinical testing	Insufficient or conflicting evidence
GeneDx	RCV000657147	SCV000571741	uncertain significance	not provided	2018-02-13	criteria provided, single submitter	clinical testing	This variant is denoted BRCA2 c.2240A>G at the cDNA level, p.Glu747Gly (E747G) at the protein level, and results in the change of a Glutamic Acid to a Glycine (GAA>GGA). Using alternate nomenclature, this variant would be defined as BRCA2 2468A>G. This variant has not, to our knowledge, been published in the literature as pathogenic or benign. BRCA2 Glu747Gly was not observed at a significant allele frequency in large population cohorts (Lek 2016). This variant is not located in a known functional domain. In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. Based on currently available evidence, it is unclear whether BRCA2 Glu747Gly is pathogenic or benign. We consider it to be a variant of uncertain significance.
Department of Pathology and Laboratory Medicine,Sinai Health System	RCV000487003	SCV000591796	uncertain significance	not specified	2014-09-10	criteria provided, single submitter	clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano	RCV000487003	SCV000600505	uncertain significance	not specified	2017-05-24	criteria provided, single submitter	clinical testing
Color	RCV000215823	SCV000903248	uncertain significance	Hereditary cancer-predisposing syndrome	2018-06-01	criteria provided, single submitter	clinical testing
Integrated Genetics/Laboratory Corporation of America	RCV000487003	SCV000918823	uncertain significance	not specified	2017-11-06	criteria provided, single submitter	clinical testing	Variant summary: The BRCA2 c.2240A>G (p.Glu747Gly) variant involves the alteration of a non-conserved nucleotide. 3/5 in silico tools predict a damaging outcome for this variant, however these predictions have yet to be confirmed by functional studies. This variant was found in 9/246080 control chromosomes at a frequency of 0.0000366, which does not exceed the estimated maximal expected allele frequency of a pathogenic BRCA2 variant (0.0007503). The variant of interest has not, to our knowledge, been reported in affected individuals via publications and/or reputable databases; nor evaluated for functional impact by in vivo/vitro studies. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as uncertain significance. Because of the absence of clinical information and the lack of functional studies, the variant is classified as a variant of uncertain significance (VUS) until additional information becomes available.
Sharing Clinical Reports Project (SCRP)	RCV000031359	SCV000053964	uncertain significance	Breast-ovarian cancer, familial 2	2010-07-30	no assertion criteria provided	clinical testing